Pacira Pharmaceuticals Inc. Hits New 52-Week High at $69.39 (PCRX)
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) hit a new 52-week high during trading hours on Thursday, Analyst Ratings Net reports. The company traded as high as $69.39 and last traded at $65.03, with a volume of 1,003,308 shares trading hands. The stock had previously closed at $60.13.
A number of research firms have recently commented on PCRX. Analysts at Wedbush reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note to investors on Monday, November 4th. They now have a $59.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Pacira Pharmaceuticals from $58.00 to $60.00 in a research note to investors on Monday, November 4th. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $56.00 to $60.00 in a research note to investors on Friday, November 1st. They now have an “overweight” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Pacira Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $55.20.
In other Pacira Pharmaceuticals news, Director John Phd Longenecker sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $55.55, for a total value of $138,875.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Pacira Pharmaceuticals has a 1-year low of $18.05 and a 1-year high of $60.59. The stock’s 50-day moving average is $53.62 and its 200-day moving average is $44.37. The company’s market cap is $2.180 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.30) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.05. The company had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.10 million. On average, analysts predict that Pacira Pharmaceuticals will post $-1.88 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.